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ABSTRACT  
 
Pemphigus vulgaris (PV) is an autoimmune disease characterized by binding of IgG 
autoantibodies to epidermal keratinocyte desmosomes. IgG autoantibodies obtained 
from a patient with mucocutaneous PV reacted with plakoglobin (Plkg) in addition to 
desmoglein-3 (Dsg3) and Dsg1. Immunofluorescence analysis confirmed that IgG 
autoantibodies, unlike antibodies from a healthy volunteer, caused disruption of cell–
cell contacts in HaCaT keratinocytes. Moreover, apoptosis was enhanced in cells treated 
with autoantibodies compared to those treated with normal antibodies. The apoptotic 
process induced by IgG autoantibodies was characterized by caspase-3 activation, Bcl-2 
depletion and Bax expression. The present report demonstrates that PV IgG 
autoantibodies promote apoptosis in HaCaT keratinocytes. 
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1. INTRODUCTION 
 
Pemphigus vulgaris (PV) is a bullous autoimmune disease of the mucocutaneous 
surfaces, characterized histologically by suprabasal acantholytic vesicles caused by the 
separation of epidermal cells. Immunofluorescence (IF) studies have demonstrated the 
presence of autoantibodies in epidermal lesions and in the serum of PV patients [1]. 
Impaired intercellular adhesion in PV seems to be due to binding of autoantibodies 
directed to the desmosomal transmembrane protein desmoglein-3 (Dsg3), a 
glycoprotein of the cadherin family of adhesion molecules [2]. It has also been 
described that PV patients can develop IgG antibodies against Dsg1 [3] and other 
antigens [4]. These autoantibodies have been shown to be pathogenic, since they are 
able to induce acantholysis in neonatal mice in passive transfer experiments [5,6]. 
Apoptosis is an important homeostatic mechanism that maintains correct cell numbers 
in tissues by balancing cell proliferation with cell death [7]. Epidermis is continuously 
renewed throughout adult life and adhesion seems to be one of the most important 
factors controlling cell growth and apoptosis in keratinocytes. It is now clear that loss of 
anchorage may cause apoptosis in epithelial cells [8,9], but little is known about 
regulation of apoptosis by cadherin-mediated cell–cell adhesion [10]. However, there is 
evidence indicating that disruption of cell–cell contacts in acantholytic skin diseases 
may in some cases provoke apoptosis of keratinocytes [11]. Moreover, previous studies 
have demonstrated that apoptosis can be induced in the human keratinocyte cell line 
HaCaT by several stimuli [12–14]. The apoptotic response is an active and 
physiological form of cell death which occurs by organized degradation of subcellular 
components. Although there are other types of cell death such as necrosis, apoptosis is 
distinguished by structural and morphological features including cell shrinkage, plasma 
membrane blebbing, mitochondrial swelling, and chromatin condensation [15]. The 
apoptotic process is usually accompanied by several changes in cellular biochemistry 
such as oligonucleosomal DNA fragmentation, caspases activation and modifications of 
the levels of Bcl-2 family members [16]. 
The aim of the present study was to investigate whether apoptosis is triggered by PV-
IgG binding to HaCaT keratinocytes, on the basis of the specific characteristics of this 
process described above. 
 
 
2. MATERIALS AND METHODS 
 
2.1. Human sera 
Serum samples were obtained from a PV patient and a normal human donor. The PV 
patient exhibited classical active mucocutaneous disease, confirmed by typical 
histological features and a titer of 1:320 of circulating anti-ICS antibodies. Sera from 
patient and control were tested by indirect IF using monkey esophagus as a tissue 
substrate. The presence of anti-Dsg1 and anti-Dsg3 autoantibodies was tested by 
enzyme-linked immunoadsorbent assay (ELISA) in the serum of the donors. Increased 
levels, expressed as index value (IV), of Dsg1 and Dsg3 immunoreactivity were found 
in the mucocutaneous PV patient, with values of 75.3 ± 5.2 and 82.5 ± 8.1, respectively, 
as compared to a healthy volunteer (1.4 ± 0.5 for Dsg1 and 0.8 ± 0.3 for Dsg3). 
 
 
2.2. Cell culture 
HaCaT cells, a human immortalized keratinocyte cell line, were a gift from Professor N. 
Fusenig (Heidelberg, Germany). Cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal calf serum, penicillin (100 U/ml) and 
streptomycin (100 µg/ml) in a 5% CO2 humidified atmosphere. Subconfluent cultures 
maintained in serum-free medium were used in all the experiments. 
  
2.3. Purification of IgG 
IgG fractions from PV patients (PV-IgG) or normal donors (N-IgG) were obtained by 
precipitation with 50% ammonium sulfate followed by affinity chromatography on 
Staphylococcus protein A conjugated to agarose beads. Bound IgG was eluted with 0.2 
M glycine/HCl, pH 3, dialyzed extensively against phosphate buffered saline (PBS), 
concentrated by ultrafiltration (Amicon), filter-sterilized, and stored at —70 °C until 
use. The IgG concentration in each fraction was estimated by nephelometry using goat 
anti-human IgG (Beckman Array 360 System). PV-IgG and N-IgG fractions were 
labeled with FITC and tested in preliminary binding studies to determine the optimal 
IgG doses for the experiments. 
 
2.4. ELISA 
The reactivity of test sera with the extracellular portions of the Dsg1 or Dsg3 peptide 
sequences, that contain pathogenic epitopes of the PV antigens, was determined using 
Dsg1 and Dsg3-coated ELISA plates purchased from MBL (Nagoya, Japan), and 
following the protocol provided by the manufacturer. All serum samples were tested in 
triplicate and the results were expressed as IVs, calculated as follows: IV = (ODsample — 
ODnegative control)/(ODpositivecontrol — ODnegative control) x 100. As recommended by the 
manufacturer, a serum sample was considered to be positive for Dsg1 or Dsg3 antibody 
if the IV exceeded 20. 
 
2.5. Western blot analysis 
HaCaT cells were incubated in the presence or absence of PV-IgG or N-IgG during 8 h. 
Western blot analysis of cell lysates was carried out after SDS–PAGE gels were 
transferred onto nitrocellulose membranes (Amersham). Membranes were incubated 
with a polyclonal rabbit antibody, anti-human Bcl-2 (Santa Cruz), or monoclonal 
antibodies, anti-human Bax, (Santa Cruz), or anti-human procaspase-3 (Transduction 
Laboratories), for 1 h at room temperature at a 1:2000 dilution. Membranes were 
washed and incubated for 1 h at room temperature with 1:10000 donkey anti-rabbit 
(Promega) or sheep antimouse immunoglobulin horseradish peroxidase conjugated 
(Amersham), for polyclonal or monoclonal antibodies, respectively. Bound antibodies 
were detected by autoradiography with enhanced chemiluminescence with ECL-Plus 
(Amersham Pharmacia Biotech). Equivalent loading was confirmed by Coomassie 
staining of an identical gel. 
 
2.6. Immunoprecipitation of HaCaT keratinocytes extracts 
Sub-confluent HaCaT keratinocytes were washed and harvested. After sonication (five 
5 s periods), cell homogenates were centrifugated and the pellet was solubilized in a 
buffer containing 10% (wt/vol) glycerol and 1% (wt/vol) Triton X-100, and stored at      
-70 °C. Protein extracts were immunoprecipitated with anti-plakoglobin antibody (Santa 
Cruz) and protein A–Sepharose (Sigma) overnight at 4 °C. Proteins were released from 
the beads by heating at 95 °C in Laemmli sample buffer for 5 min and separated on 
discontinued SDS–polyacrylamide gels. Blots of immunoprecipitated samples were 
incubated with 50 µg/ml of purified PV-IgG diluted 1:2000 for 2 h at room temperature 
and then with a goat anti-human antibody (Sigma) diluted 1:10000. After stripping, the 
membrane was incubated for 2 h at room temperature with an anti-plakoglobin antibody 
(Santa Cruz) diluted 1:2000 and with a donkey anti-goat antibody (Santa Cruz) diluted 
1:10000. 
 
2.7. IF microscopy 
Cells were grown directly on glass coverslips and incubated in the presence or absence 
of 2.0 mg/ml of PV-IgG or N-IgG. After 24 h, HaCaT cells were rinsed with PBS at 
room temperature and dipped for 7 min in —20 °C methanol. Fixed cells were 
incubated with a monoclonal anti-human keratin antibody (LP34 clon, DAKO) at a 1:20 
PBS dilution for 45 min and then incubated with a rabbit anti-mouse IgGFITC (DAKO) 
at a 1:20 PBS dilution for 45 min. Coverslips were washed in PBS and mounted over 
glass slides in 50% glycerol in PBS. 
 
2.8. Microscopic analysis 
Morphologic examination of nuclei was performed using fluorescence microscopy. 
Cells were grown directly on glass coverslips and incubated in the presence or absence 
of 1.0 mg/ml of purified PV-IgG or N-IgG, during 8 h. Thereafter, cells were fixed with 
—20 °C cold methanol for 8 min, washed in PBS for 10 min, incubated with 5% BSA 
in PBS for 10 min, washed three times and stained by Hoechst 33342 (50 µg/ml) 
(Sigma) in PBS for 30 min. Coverslips were washed three times in PBS and mounted 
over glass slides in 50% glycerol in PBS. 
 
2.9. Determination of oligonucleosomal (histone-associated) DNA fragments 
The presence of soluble histone–DNA complexes was measured by the Cell Death 
Detection Assay (Boehringer Mannheim). Cells were seeded on 24-well plates and 8 h 
after addition of N-IgG or PV-IgG, or 10 µg/ml camptothecin (Sigma), supernatant was 
discarded and cell death ELISA assays were performed according to the manufacturer’s 
instructions. Specific enrichment of mono- and oligonucleosomes released into the 
cytoplasm [Enrichment Factor, (EF)] was calculated as the ratio between the absorbance 
of the sample and the absorbance of the corresponding control sample (untreated cells). 
 
2.10. Statistical analysis 
The data were analyzed using the Kruskal–Wallis test to determine differences between 
all independent groups. When significant differences were obtained (P < 0.05), 
differences between two groups were tested using the Mann–Whitney U test. 
 
 
3. RESULTS AND DISCUSSION 
 
3.1. Characterization of IgG antibodies from a mucocutaneous PV patient 
Immunoprecipitation of HaCaT keratinocytes extracts with an antibody against 
plakoglobin (Plkg) was used to identify the immunoreactivity of the autoantibodies 
obtained from a mucocutaneous PV patient (PV-IgG). Western blot analysis of 
immunocomplexes-containing samples with PV-IgG revealed the presence of three 
main immunoreactive bands, corresponding to 160, 130 and 85 kDa molecular weights 
(Fig. 1A). The two higher bands could contain Dsg1 and Dsg3, respectively, since their 
molecular weights were coincident and the presence of anti-Dsg1 and anti-Dsg3 
antibodies had been already determined by ELISA (see Section 2). Although Dsg1 is 
the autoantigen characteristic of pemphigus foliaceus, it is now accepted that 25–66% of 
the patients with PV present antibodies anti-Dsg1, together with the specific PV 
autoantibodies anti-Dsg3 [17,18]. In fact, the detection of both antibodies in the serum 
of the PV patient agreed with his diagnosis of mucocutaneous PV, which is 
characterized by the presence of anti-Dsg1 and anti-Dsg3 [19]. 
Binding of PV-IgG autoantibodies to Plkg was assessed by Western blot analysis using 
an anti-plakoglobin antibody after stripping of the blot (Fig. 1B). Previous 
immunoprecipitation studies had detected the presence of anti-plakoglobin antibodies in 
the serum of PV patients [4]. Plkg plays an important role in the assembling of 
desmosomes and their interaction with intermediate filaments of keratin [20]. 
Interestingly, keratinocytes derived from Plkg knock-out mice are resistant to the 
pathogenic effect of PV antibodies, suggesting that the linkage of desmosomal Dsg3 to 
the cytoskeleton via Plkg might have a central role in the molecular events leading to 
acantholysis [21]. 
 
 
3.2. PV-IgG provokes disruption of cell–cell contacts in HaCaT keratinocytes 
IF experiments performed in cultured HaCaT keratinocytes showed that incubation with 
PV-IgG induced specific changes in intercellular unions. When compared to untreated 
cells (Fig. 2A), or cells incubated with N-IgG (Fig. 2B), PV-IgGtreated cells presented 
loss of cell–cell interactions (Fig. 2C). The main histopathological characteristic of PV 
is acantholysis of epidermis provoked by the disruption of keratinocyte intercellular 
interactions. This disruption seems to be a consequence of signaling pathways triggered 
by the binding of PV-IgG antibodies to keratinocytes, as has been shown by different in 
vivo and in vitro studies [22–24]. Therefore, PVIgG antibodies were able to produce in 
cultured HaCaT keratinocytes an effect similar to the features observed in animal 
models of PV and human patients affected by this disease. In the following experiments, 
we used this cell line to analyze other possible effects that PV-IgG could cause on 
human epidermal cells in PV disease. 
 
3.3. Apoptotic effect of PV-IgG on HaCaT keratinocytes 
We investigated whether PV-IgG induces the apoptotic response in HaCaT cells, which 
are susceptible to apoptosis caused by other inducers [12,25]. For this purpose, two 
different experimental approaches were used: detection of nuclear changes 
characteristic of apoptosis by staining of the cells with the fluorescent probe Hoechst 
3342, and determination of oligonucleosomal fragments of DNA accumulated in 
cytoplasmic fractions as a consequence of the DNA fragmentation that occurs during 
the apoptotic process. As shown in Fig. 3A, PVIgG-treated cells presented chromatin 
condensation that was not observed in untreated cells (control), or was observed only in 
few of the cells incubated with IgG from a healthy donor (N-IgG). On the other hand, 
PV-IgG induced internucleosomal DNA fragmentation in a dose-dependent manner in 
the concentration range from 0.1 to 1.0 mg/ml, with maximum values of 2.5-fold 
increase (Fig. 3B). N-IgG was also capable to provoke a slight increase in cytoplasmic 
oligonucleosomal content at a 1.0 mg/ml concentration, probably due to the binding of 
IgG to the FcR present in keratinocytes [26]. Indeed, binding of IgG to FcR in other cell 
types has been previously shown to induce apoptosis [27]. 
In additional experiments using IgG fractions from another patient affected by 
mucocutaneous PV, we also observed the capacity of these samples to cause apoptosis. 
However, the apoptotic effect was not observed with IgG fractions from mucous PV 
patients, indicating that autoantibodies against antigens other than Dsg3, not present in 
the mucous PV sera, were required to cause apoptosis (data not shown). 
In time course studies, apoptosis induced by IgG from a mucocutaneous PV patient was 
only observed after 6 h of exposure of the cells with the autoantibodies. Increased levels 
of apoptosis were obtained at different time points of treatment between 6 and 12 h with 
the autoantibodies (Fig. 3C). 
 
3.4. Mechanisms of apoptosis induced by PV-IgG in HaCaT keratinocytes 
Caspases are key mediators in apoptosis of different cell types provoked by most 
apoptotic inducers [28]. Caspase-3 is an effector caspase that causes the cleavage of 
several proteins, such as PARP, DFF45, lamins, etc. [29,30]. The involvement of 
caspase-3 in the apoptotic process induced by IgG from a mucocutaneous PV patient in 
HaCaT cells was assessed by analysis of the activation of this enzyme by proteolysis of 
its inactive form, procaspase-3. Immunodetection by Western blot of the levels of 
procaspase-3 showed that a decrease in this form was produced by treatment of HaCaT 
cells with 0.5 or 1.0 mg/ml PV-IgG, indicating an increase of its proteolytic activity 
(Fig. 4A). These results were confirmed by pretreatment of HaCaT cells with the 
caspase-3 inhibitor Ac-DVEDCHO. The accumulation of oligonucleosomal cytosolic 
fragments induced by PV-IgG was totally prevented by this pretreatment (Fig. 4B). 
The susceptibility of cells to apoptosis is controlled by the ratio of pro-apoptotic and 
anti-apoptotic members of Bcl-2 family proteins. It has been demonstrated that high 
levels of Bcl2 protect HaCaT keratinocytes from apoptotic stimuli [31,32] and that Bax 
protein is enhanced by treatment of this same cell line with some apoptosis inducers 
[33]. In our experiments, levels of the pro-apoptotic protein Bax and the anti-apoptotic 
protein Bcl-2 were determined by Western blot. We found that PV-IgGtreated HaCaT 
cells presented increased levels of Bax and decreased levels of Bcl-2 at the two 
concentrations tested, as compared to untreated cells (Fig. 5). As expected, N-IgG 
produced a slight effect on the apoptotic parameters analyzed only at higher 
concentration (Figs. 4A and 5B). 
In the present work, apoptosis induction of human HaCaT keratinocytes by IgG 
autoantibodies obtained from a patient with mucocutaneous PV has been assessed. In 
epidermis apoptosis plays an important role in maintaining homeostasis in physiological 
situations, and also disturbed apoptosis is involved in a variety of pathological 
conditions. Moreover, the involvement of Fas-L-induced apoptosis in the development 
of acantholysis in PV has been previously shown [34]. The results obtained in this study 
suggest that PV-IgG autoantibodies could contribute to the pathogenesis of 
mucocutaneous PV by triggering apoptosis of epidermal keratinocytes. Dsg3 can in fact 
be cleaved by caspase-3 [35], also pointing to the involvement of apoptosis in PV 
development. In the same way, Nguyen et al. [36] have recently shown that the anti-
acantholytic effect of methylprednisolone is well correlated with increased expression 
of several adhesion proteins, including Dsg3. 
The contradictory results obtained by various investigators, related to the involvement 
of different pemphigus autoantibodies in acantholysis induction [37,38], might reflect 
that apoptosis triggered by several alternative inducers, including autoantibodies and 
other factors present in PV patients sera such as the Fas-L, could participate in the 
subsequent acantholytic process associated with these types of diseases. 
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Figure 1. Western blot analysis of the immunoprecipitated extracts from HaCaT cells 
obtained with an anti-plakoglobin antibody. (A) Immunoreactivity of IgG purified from 
a patient with mucocutaneous PV (PV-IgG). (B) Identification of Plkg after stripping of 
the same blot. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. IF staining of cytoskeletal proteins in HaCaT keratinocytes. Cells were 
treated for 24 h with 2.0 mg/ml of IgG purified from a healthy donor (N-IgG) or 
purified from a patient with mucocutaneous PV (PV-IgG). After treatment, cells, 
including untreated controls, were incubated with an antibody anti-cytokeratin as 
described in Section 2. 
 
 
 
Figure 3. Apoptosis of HaCaT keratinocytes induced by IgG from a mucocutaneous PV 
patient. (A) Nuclei staining of HaCaT keratinocytes using Hoechst 33342. Cells were 
incubated for 8 h with 1.0 mg/ml IgG purified from a healthy donor (N-IgG) or from a 
patient with mucocutaneous PV (PV-IgG). Original magnification 1000x. (B) Dose–
response apoptotic effect of PV-IgG on HaCaT cells. HaCaT keratinocytes were treated 
for 8 h with the indicated concentrations of N-IgG or PV-IgG. Treatment with 10 lg/ml 
camptothecin was used as a positive control. (C) Time course study of the apoptotic 
effect of PV-IgG. HaCaT keratinocytes were treated with 1.0 mg/ml of PV-IgG 
fractions. Apoptosis was measured as accumulation of oligonucleosomal fragments in 
cytoplasmic extracts. Oligonucleosomal fragments content was expressed as EF, as 
described in Section 2. Each bar represents the mean±S.D. of quadruplicate 
determinations from at least three independent experiments (*P < 0:05, **P < 0:01, vs 
control). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Role of caspase-3 in the apoptosis of HaCaT cells induced by PV-IgG. (A) 
Western blot analysis of procaspase-3 levels in HaCaT keratinocytes untreated or 
treated for 8 h with N-IgG or PV-IgG (0.5 and 1.0 mg/ml). (B) Determination of 
oligonucleosomal fragments in cytoplasmic extracts from HaCaT keratinocytes 
incubated in control medium or in the presence of either N-IgG or mucocutaneous PV-
IgG, after pretreatment with the caspase-3 inhibitor Ac-DEVD-CHO (30 µg/ml) during 
30 min, when indicated. HaCaT keratinocytes were treated with 0.5 and 1.0 mg/ml N-
IgG or PV-IgG for 8 h. Oligonucleosomal fragments content was expressed as EF, as 
described in Section 2. Each bar represents the mean±S.D. of quadruplicate 
determinations from at least three independent experiments (*P < 0:05, **P < 0:01, vs 
control). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Western blot analysis of Bax and Bcl-2 proteins in HaCaT keratinocytes 
incubated in the presence or absence of either N-IgG or PV-IgG. HaCaT keratinocytes 
were treated for 8 h with 0.5 mg/ml (A) or 1.0 mg/ml (B) of N-IgG and PV-IgG. β-
Actin was used as a control for loading. 
